Search Results - "Nichols, C. R."

Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy by Kollmannsberger, C., Moore, C., Chi, K.N., Murray, N., Daneshmand, S., Gleave, M., Hayes-Lattin, B., Nichols, C.R.

“…With treatment leading to nearly uniform cure in clinical stage I nonseminomatous testicular cancer (CSI-NSGCT), diminishing treatment-related morbidity has…”
Get full text

Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor by Loehrer, Sr, P J, Gonin, R, Nichols, C R, Weathers, T, Einhorn, L H

“…This study was designed to assess the effectiveness of vinblastine, ifosfamide, and cisplatin (VeIP) as second-line therapy in patients with recurrent germ…”
Get more information

High-Dose Chemotherapy as Initial Salvage Chemotherapy in Patients With Relapsed Testicular Cancer by BHATIA, S, ABONOUR, R, PORCU, P, SESHADRI, R, NICHOLS, C. R, CORNETTA, K, EINHORN, L. H

“…To assess the role of high-dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer. From August 1992 to April 1998, 65…”
Get full text

Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study by Nichols, C R, Catalano, P J, Crawford, E D, Vogelzang, N J, Einhorn, L H, Loehrer, P J

“…To compare standard therapy with bleomycin, etoposide, and cisplatin (BEP) to experimental therapy with etoposide, ifosfamide, and cisplatin (VIP) as primary…”
Get more information

Prognostic variables for response and outcome in patients with extragonadal germ-cell tumors by Hartmann, J. T., Nichols, C. R., Droz, J.-P., Horwich, A., Gerl, A., Fossa, S. D., Beyer, J., Pont, J., Kanz, L., Einhorn, L., Bokemeyer, C.

“…Background: This investigation evaluates prognostic variables in patients with seminomatous and non-seminomatous extragonadal germ-cell tumors (EGCT) in order…”
Get full text

High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables by Beyer, J, Kramar, A, Mandanas, R, Linkesch, W, Greinix, A, Droz, J P, Pico, J L, Diehl, A, Bokemeyer, C, Schmoll, H J, Nichols, C R, Einhorn, L H, Siegert, W

“…To identify prognostic variables for response and survival in male patients with relapsed or refractory germ cell tumors treated with high-dose chemotherapy…”
Get more information

Hematologic disorders associated with primary mediastinal nonseminomatous germ cell tumors by HARTMANN, J. T, NICHOLS, C. R, KANZ, L, BOKEMEYER, C, DROZ, J.-P, HORWICH, A, GERL, A, FOSSA, S. D, BEYER, J, PONT, J, FIZAZI, K, EINHORN, L

“…The association between primary germ cell tumors of the mediastinum (the space between the lung pleura that contains the heart and other chest viscera) and…”
Get full text

Protons Safely Allow Coverage of High-Risk Nodes for Patients with Regionally Advanced Non-Small-Cell Lung Cancer by Nichols, R. C., Huh, S. H., Hoppe, B. S., Henderson, R. H., Li, Z., Flampouri, S., D'Agostino, H. J., Cury, J. D., Pham, D. C., Mendenhall, N. P.

“…Our objective was to determine if protons allow for the expansion of treatment volumes to cover high-risk nodes in patients with regionally advanced…”
Get full text

Wisconsin Ginseng (Panax quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind Trial, N07C2 by BARTON, Debra L, HESHAN LIU, LOPRINZI, Charles L, DAKHIL, Shaker R, LINQUIST, Breanna, SLOAN, Jeff A, NICHOLS, Craig R, MCGINN, Travis W, STELLA, Philip J, SEEGER, Grant R, SOOD, Amit

“…Safe, effective interventions to improve cancer-related fatigue (CRF) are needed because it remains a prevalent, distressing, and activity-limiting symptom…”
Get full text

Testicular Cancer Survivorship: Research Strategies and Recommendations by Travis, Lois B., Beard, Clair, Allan, James M., Dahl, Alv A., Feldman, Darren R., Oldenburg, Jan, Daugaard, Gedske, Kelly, Jennifer L., Dolan, M. Eileen, Hannigan, Robyn, Constine, Louis S., Oeffinger, Kevin C., Okunieff, Paul, Armstrong, Greg, Wiljer, David, Miller, Robert C., Gietema, Jourik A., van Leeuwen, Flora E., Williams, Jacqueline P., Nichols, Craig R., Einhorn, Lawrence H., Fossa, Sophie D.

“…Testicular cancer represents the most curable solid tumor, with a 10-year survival rate of more than 95%. Given the young average age at diagnosis, it is…”
Get full text

Adjuvant bleomycin, etoposide and cisplatin in pathological stage II non-seminomatous testicular cancer: the Indiana University experience by Behnia, M, Foster, R, Einhorn, L.H, Donohue, J, Nichols, C.R

“…Two cycles of bleomycin, etoposide, and cisplatin (BEP) were evaluated as adjuvant chemotherapy for patients with pathological stage II non-seminomatous germ…”
Get full text

Mediastinal germ cell tumors. Clinical features and biologic correlates by Nichols, C R

Get more information

Second-Line Chemotherapy in Patients With Relapsed Extragonadal Nonseminomatous Germ Cell Tumors: Results of an International Multicenter Analysis by HARTMANN, Jörg T, EINHORN, Lawrence, KANZ, Lothar, BOKEMEYER, Carsten, NICHOLS, Craig R, DROZ, Jean-P, HORWICH, Alan, GERL, Arthur, FOSSA, Sophie D, BEYER, Jörg, PONT, Jörg, SCHMOLL, Hans-J

“…Relapsed extragonadal germ cell tumors patients (EGGCT) are treated with identical salvage chemotherapy regimens, as are patients with metastatic testicular…”
Get full text

Secondary leukemia associated with a conventional dose of etoposide: review of serial germ cell tumor protocols by Nichols, C R, Breeden, E S, Loehrer, P J, Williams, S D, Einhorn, L H

“…Case reports have suggested that treatment with high-dose etoposide can result in development of a unique secondary leukemia. This study was designed to…”
Get more information

Plasma miR-371a-3p for detection of non-teratomatous viable germ cell tumor in testicular cancer by Nappi, L., Thi, M., Eigl, B.J., Lum, A., Huntsman, D., Martin, C., Neil, B.O., Khalaf, D.J., Chi, K.N., Gleave, M.E., So, A., Black, P., Daneshmand, S., Nichols, C.R., Kollmannsberger, C.K.

Get full text

Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation by Nichols, C R, Tricot, G, Williams, S D, van Besien, K, Loehrer, P J, Roth, B J, Akard, L, Hoffman, R, Goulet, R, Wolff, S N

“…Between September 1986 and March 1988, 33 patients with refractory germ cell cancer were entered on a phase I/II trial of two courses of high-dose carboplatin…”
Get more information

Incidence of Metachronous Testicular Cancer in Patients With Extragonadal Germ Cell Tumors by Hartmann, Jörg T., Fossa, Sophie D., Nichols, Craig R., Droz, Jean-Paul, Horwich, Alan, Gerl, Arthur, Beyer, Jörg, Pont, Jörg, Fizazi, Karim, Hecker, Hartmut, Kanz, Lothar, Einhorn, Lawrence, Bokemeyer, Carsten

“…Background: The frequency of subsequent testicular cancer (referred to as metachronous testicular cancer) in men who have had previous testicular cancer is…”
Get full text

Salvage chemotherapy in patients with extragonadal nonseminomatous germ cell tumors: the Indiana University experience by Saxman, S B, Nichols, C R, Einhorn, L H

“…Patients with relapsed extragonadal germ cell tumors (EGCT) are usually treated in an identical fashion as patients with recurrent testicular cancer. However,…”
Get more information

Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial by Loehrer, Sr, P J, Elson, P, Dreicer, R, Hahn, R, Nichols, C R, Williams, R, Einhorn, L H

“…This multicenter cooperative group phase I/II trial evaluated the toxicity and efficacy of escalated dosages of methotrexate, vinblastine, doxorubicin, and…”
Get more information

The pandemic of Salmonella Enteritidis phage type 4 reaches Utah: a complex investigation confirms the need for continuing rigorous control measures by SOBEL, J., HIRSHFELD, A. B., McTIGUE, K., BURNETT, C. L., ALTEKRUSE, S., BRENNER, F., MALCOLM, G., MOTTICE, S. L., NICHOLS, C. R., SWERDLOW, D. L.

“…In 1995, Salmonella Enteritidis (SE) cases in the state of Utah increased fivefold. Isolates were identified as phage type 4 (PT4). Risk factors and sources of…”
Get full text